HealthDay News — Trajectories of emotion regulation across ages 3 to 7 years predict attention-deficit/hyperactivity disorder (ADHD) symptoms, as well as conduct problems, according to a study ...

HealthDay News — Work-time activity behavior, rather than leisure-time or non-workday, seems to be associated with 24-hour ambulatory blood pressure, according to a study published online in Medicine ...

At ObesityWeek 2024, researchers presented the latest data on treatment regimens for chronic weight management, including GLP ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

The American Academy of Sleep Medicine published guidance regarding the treatment of restless leg syndrome and periodic limb movement disorder.

After peak in 2020, significant decrease seen in firearm injury-related visit rates year over year from 2020 to 2023 ...

The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults an ...

Researchers assessed the safety and efficacy of apremilast over a 48-week period for the treatment of early oligoarticular psoriatic arthritis.

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks.

No new safety concerns were observed through 16 weeks among pediatric patients with juvenile psoriatic arthritis or enthesitis-related arthritis receiving ixekizumab. Ixekizumab (IXE) demonstrated ...

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates ...